Viridian Announces Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 In Patients With Chronic Thyroid Eye Disease
Portfolio Pulse from Benzinga Newsdesk
Viridian has announced data from its ongoing Phase 1/2 trial evaluating VRDN-001 in patients with chronic Thyroid Eye Disease (TED). The data showed clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001. The company has amended its ongoing THRIVE Phase 3 trial based on this data and stakeholder feedback. Viridian also plans to select a lead subcutaneous (SC) program candidate by the end of 2023.
July 10, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viridian's VRDN-001 has shown promising results in the ongoing Phase 1/2 trial for treating chronic TED. This could potentially lead to a positive impact on the company's stock.
The positive results from the Phase 1/2 trial of VRDN-001 indicate that the drug is effective in treating chronic TED. This could potentially lead to increased demand for the drug, which would positively impact Viridian's revenues and, consequently, its stock price. The company's decision to amend its ongoing THRIVE Phase 3 trial based on this data and stakeholder feedback also shows its confidence in the drug's potential, which could further boost investor confidence.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100